V K Vaishnavi Vedam1, Karen Boaz2, Srikant Natarajan2, Sivadas Ganapathy3. 1. Department of Oral Pathology & Microbiology, Faculty of Dentistry, Asian Institute of Medicine, Science and Technology (AIMST) University, Kedah, Malaysia. 2. Department of Oral Pathology & Microbiology, Manipal College of Dental Sciences, Mangalore, Manipal University, Mangalore, India. 3. Department of Pedodontics & Preventive Dentistry, Faculty of Dentistry, Asian Institute of Medicine, Science and Technology (AIMST) University, Kedah, Malaysia.
Abstract
BACKGROUND: The aim of this study was to evaluate salivary amylase in patients with primary oral cancer undergoing radiotherapy as the main modality of treatment. MATERIALS/ METHODS: The study was conducted on ten histologically proven cases of oral cancer undergoing radiotherapy. Stimulated whole saliva was collected at three stages of radiotherapy-0, 3, and 6 weeks. Salivary amylase was estimated using Henry-Chiamori method and comparison was made with appropriate age- and gender-matched controls. RESULTS: Salivary amylase levels showed significant decrease in healthy subjects when compared to oral cancer patients (P < 0.001). The latter group also showed changing trend with initial decrease from 0 to 3 weeks followed by increase from 3 to 6 weeks following radiotherapy (P < 0.0528). CONCLUSIONS: The trend in changes in the levels of salivary amylase could be used as a surrogate marker of salivary gland function in patients with oral cancer undergoing radiotherapy as primary treatment.
BACKGROUND: The aim of this study was to evaluate salivary amylase in patients with primary oral cancer undergoing radiotherapy as the main modality of treatment. MATERIALS/ METHODS: The study was conducted on ten histologically proven cases of oral cancer undergoing radiotherapy. Stimulated whole saliva was collected at three stages of radiotherapy-0, 3, and 6 weeks. Salivary amylase was estimated using Henry-Chiamori method and comparison was made with appropriate age- and gender-matched controls. RESULTS: Salivary amylase levels showed significant decrease in healthy subjects when compared to oral cancerpatients (P < 0.001). The latter group also showed changing trend with initial decrease from 0 to 3 weeks followed by increase from 3 to 6 weeks following radiotherapy (P < 0.0528). CONCLUSIONS: The trend in changes in the levels of salivary amylase could be used as a surrogate marker of salivary gland function in patients with oral cancer undergoing radiotherapy as primary treatment.
Authors: Mayte Arce-Franco; María Dominguez-Luis; Martina K Pec; Carlos Martínez-Gimeno; Pablo Miranda; Diego Alvarez de la Rosa; Teresa Giraldez; José María García-Verdugo; José David Machado; Federico Díaz-González Journal: Sci Rep Date: 2017-09-19 Impact factor: 4.379
Authors: Evelin Bachmeier; María Elena Migueles Goitea; Jorge Alberto Linares; Fernando Martin Wietz; Sol Jarchum; Gustavo Jarchum; Mabel Noemi Brunotto; Marcelo Adrian Mazzeo Journal: Rev Fac Cien Med Univ Nac Cordoba Date: 2021-12-28